Product Code: GVR-4-68040-071-5
Heart Pump Device Market Growth & Trends:
The global heart pump device market size is estimated to reach USD 6.39 billion by 2030, expanding at a CAGR of 13.6 % from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of coronary artery disease, ischemic heart disease, and other CVD diseases is anticipated to boost the demand for heart pump devices. For instance, according to data published by British Heart Foundation, in 2022, about 7.6 million individuals in the UK live with heart disease, and each year, around 160,000 people die from CVD and other heart-related conditions in the UK. Moreover, according to WHO data in 2020, coronary heart disease caused 163,905 deaths in Japan, with 121,823 or 11.03% of total deaths were caused due to stroke.
Furthermore, the market is anticipated to grow by increasing support and awareness initiatives for disease awareness. For instance, in January 2022, The School of Medical Research and Technology at IIT Kanpur launched Hridyantra, a challenge-based program. Its objective is to create an advanced artificial heart called a Left Ventricular Assist Device (LVAD) for patients with end-stage heart failure (HF). Hridyantra aims to improve the available treatment options for HF patients. This program is expected to significantly improve the treatment options available for patients with HF, thereby driving market growth.
Heart Pump Device Market Report Highlights:
- Based on type, the implanted heart pump devices segment accounted for the largest revenue share of 69.1% of the market in 2024, due to their ability to assist with pumping blood and serve as a bridge to transplantation or a permanent therapy option for HF patients.
- Based on product, ventricular assist devices (VADs) held the largest market share of 68.5 % in 2024. It is estimated to register the fastest CAGR of 14.8% during the forecast period; owing to the increasing prevalence of HF worldwide, the demand for VADs is anticipated to grow rapidly over the forecast period.
- Based on end-use, the hospital segment dominated the market in 2024, attributed to the high number of surgeries performed in hospitals.
- North America is expected to dominate the market with over 52.59% revenue share in 2024 due to the high prevalence of heart failure, growing aging population, and robust healthcare system.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Product
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type Segment
- 2.2.2. Product Segment
- 2.2.3. End Use Segment
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Heart Pump Device Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Heart Pump Device Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.4. Heart Pump Device Market: Pipeline Analysis
Chapter 4. Heart Pump Device Market: Type Estimates & Trend Analysis
- 4.1. Type Segment Dashboard
- 4.2. Heart Pump Device Market: Type Movement Analysis
- 4.3. Global Heart Pump Device Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. Implanted Heart Pump Devices
- 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Extracorporeal Heart Pump Devices
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Heart Pump Device Market: Product Estimates & Trend Analysis
- 5.1. Product Segment Dashboard
- 5.2. Heart Pump Device Market: Product Movement Analysis
- 5.3. Global Heart Pump Device Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 5.4. Ventricular Assist Devices (VADs)
- 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Left Ventricular Assist Devices (LVAD)
- 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Right Ventricular Assist Devices (RVAD)
- 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Bi-Ventricular Assist Devices (BiVAD)
- 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Percutaneous Ventricular Assist Devices (PVAD)
- 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Intra-Aortic Balloon Pumps (IABPs)
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Extracorporeal Membrane Oxygenation (ECMO)
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Heart Pump Device Market: End Use Estimates & Trend Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Heart Pump Device Market: End Use Movement Analysis
- 6.3. Global Heart Pump Device Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 6.4. Hospitals
- 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Cardiac Centers
- 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Research Institute
- 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Heart Pump Device Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Dashboard
- 7.2. Regional Market Share Analysis, 2024 & 2030
- 7.3. Continuous bioprocessing market by Region: Key Takeaways
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Norway
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework/ reimbursement structure
- 7.5.7.3. Competitive scenario
- 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework/ reimbursement structure
- 7.5.8.3. Competitive scenario
- 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Japan
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. China
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.3. India
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework/ reimbursement structure
- 7.6.3.3. Competitive scenario
- 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework/ reimbursement structure
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework/ reimbursement structure
- 7.6.5.3. Competitive scenario
- 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework/ reimbursement structure
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework/ reimbursement structure
- 7.8.1.3. Competitive scenario
- 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework/ reimbursement structure
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework/ reimbursement structure
- 7.8.3.3. Competitive scenario
- 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework/ reimbursement structure
- 7.8.4.3. Competitive scenario
- 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2024
- 8.4. Company Profiles
- 8.4.1. Abbott
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. ABIOMED (Johnson & Johnson Services, Inc.)
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Getinge
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. LivaNova PLC
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Berlin Heart
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Picard Medical, Inc. (SynCardia Systems, LLC)
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Jarvik Heart, Inc
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. BiVACOR Inc.
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Leviticus Cardio
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. Teleflex Incorporated
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Product benchmarking
- 8.4.10.4. Strategic initiatives